ArticleERJ open research2026
Effect of short-term supplemental oxygen therapy on 6-min walk distance in highlanders at risk for pulmonary hypertension: a randomised, crossover trial.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Little is known about the effects of portable supplemental oxygen therapy (SOT) to improve exercise performance in highlanders at risk for high-altitude pulmonary hypertension (HAPH). We aimed to investigate whether SOT improves the 6-min walk distance (6MWD) and reduces perceived dyspnoea in highlanders at risk for HAPH. Methods: In a pragmatic randomised open-label crossover trial, adult highlanders, living >2500 m, with a peak tricuspid regurgitation velocity >2.8 m·s Results: 47 highlanders (44% male, mean±sd age of 52±12 years, TRPG of 41±10 mmHg and oxygen saturation ( Conclusion: In hypoxaemic highlanders at risk for HAPH, portable low-dose SOT did not improve 6MWD, despite lower dyspnoea perception, lower heart rates and higher
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.